[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532312":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":52,"responsibleParty":83,"collaborators":10,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":10,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":10,"maxAge":10,"enrollmentInfo":94,"targetDuration":10,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Acute Leukemia",null,"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia",[13,14,15],"Diagnostic Test: Digital PCR","Diagnostic Test: Quantitative PCR","Diagnostic Test: MFC",{"label":17,"type":10,"description":18,"interventionNames":19},"MDS or MDS\u002FMPN","Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and other subtypes of Myelodysplastic\u002FMyeloproliferative Neoplasm",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"CML","Chronic Myeloid Leukemia",[13,14],[25,30,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DIAGNOSTIC_TEST","Digital PCR","digital Polymerase Chain Reaction (dPCR)",[9,21,17],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Quantitative PCR","Real-time Polymerase Chain Reaction (real-time PCR)",[9,21,17],{"type":26,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"MFC","Multicolor Flow Cytometry",[9,17],[39],{"name":40,"affiliation":5,"role":41},"Xiao-jun Huang, M.D","PRINCIPAL_INVESTIGATOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Meng Lv, M.D,Ph.D","CONTACT","+861088324637","drlvmeng@163.com",{"name":49,"role":45,"phone":50,"phoneExt":10,"email":51},"Ya-zhen Qin, Ph.D","+861088324702","qin2000@aliyun.com",[53],{"facility":5,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":61,"coordinates":62},"Point",[63,64],116.39723,39.9075,{"lat":64,"lon":63},[67,71,73,76,77,79,81],{"name":68,"role":45,"phone":69,"phoneExt":10,"email":70},"Zi-qi Han, BS","+861088324577","ncrch_pku@163.com",{"name":72,"role":41,"phone":10,"phoneExt":10,"email":10},"Xiao-jun Huang",{"name":74,"role":75,"phone":10,"phoneExt":10,"email":10},"Meng Lv, M.D, Ph.D","SUB_INVESTIGATOR",{"name":49,"role":75,"phone":10,"phoneExt":10,"email":10},{"name":78,"role":75,"phone":10,"phoneExt":10,"email":10},"Xiao-su Zhao, M.D,Ph.D",{"name":80,"role":75,"phone":10,"phoneExt":10,"email":10},"Jing Liu, M.D,Ph.D",{"name":82,"role":75,"phone":10,"phoneExt":10,"email":10},"Ying-jun Chang, M.D,Ph.D",{"type":41,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xiao-Jun Huang","Professor","100532312","assessment-of-measurable-residual-disease-in-allo-hsct-using-digital-polymerase-chain-reaction-100532312",false,"NCT06211166","Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction","Predicting Patient Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Measurable Residual Disease (MRD) Assessment by Digital Polymerase Chain Reaction and Conventional MRD","Inclusion Criteria:\n\n* The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring.\n* Neutrophil engraftment\n* Received at least one MRD monitoring by digital PCR after HSCT\n\nExclusion Criteria:\n\n* Patients who relapsed or died before the first digital PCR monitoring\n* Patients only with mutations in DNMT3A, TET2, and ASXL1 (\"DTA mutations\") or only germline mutations","ALL",{"count":95,"type":96},300,"ESTIMATED","OBSERVATIONAL","A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.",[9,100,101,21],"MDS","MDS\u002FMPN",[103,104,105,106],"dPCR","MRD","allo-HSCT","leukemia","2024-01-08",{"date":109,"type":110},"2024-01-18","ACTUAL",{"date":107,"type":110},{"date":113,"type":96},"2027-12-31",{"name":5,"class":6},1]